Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
BMC Cardiovasc Disord ; 24(1): 58, 2024 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-38238660

RESUMEN

BACKGROUND: The effect of different dual antiplatelet therapies on thrombotic events on the background of intravascular ultrasound (IVUS) guidance is unclear. We investigated whether ticagrelor can provide any additional benefit to clopidogrel in reducing thrombotic events in acute coronary syndrome (ACS) treated with drug- eluting stent (DES), when guided by IVUS or not. METHODS: A total of 5,666 ACS patients who underwent DES implantation and who were discharged on dual antiplatelet therapy were enrolled and grouped according to the use of IVUS or not. Each group was subdivided into two subgroups according to the type of P2Y12 inhibitor used after discharge. Propensity score matching (PSM) was used between the IVUS and no-IVUS groups. Covariate adjustment of Cox proportional hazards model was used between the ticagrelor and clopidogrel groups. Thrombotic event at 12 months was compared in groups separately. RESULTS: After PSM, 12-month follow-up data were available for 1,174 patients. Major adverse cardiac events (MACE) were less frequent in the IVUS-guided group (2.2% vs. 4.3%, P = 0.081) with a trend toward statistical significance. Comparison of antiplatelet regimens revealed significantly fewer major adverse cardiac and cerebrovascular events (MACCE) with ticagrelor in the entire PSM cohort and angiography-guided subgroup (2.9% vs. 5.7%, P = 0.035; 3.1% vs. 6.4%, P = 0.020, respectively). Among patients in the IVUS-guided group the outcome was comparable (2.5% vs. 4.4%, P = 0.312). Ticagrelor was associated with increasing bleeding incidence in the entire PSM cohort (1.3% vs. 3.3%, P = 0.030), mainly due to Bleeding Academic Research Consortium type 2 bleeding (0.7% vs. 2.6%, P = 0.010). The results were consistent after covariate adjustment of Cox proportional hazards model. CONCLUSION: The comparison of ischemic benefit between ticagrelor and clopidogrel was similar in patients receiving IVUS guidance during stent implantation, probably due to the precise implantation of IVUS. Multicenter, randomized studies should be performed to validate this conclusion.


Asunto(s)
Síndrome Coronario Agudo , Stents Liberadores de Fármacos , Intervención Coronaria Percutánea , Trombosis , Humanos , Síndrome Coronario Agudo/diagnóstico por imagen , Síndrome Coronario Agudo/terapia , Síndrome Coronario Agudo/etiología , Clopidogrel/efectos adversos , Angiografía Coronaria/efectos adversos , Stents Liberadores de Fármacos/efectos adversos , Intervención Coronaria Percutánea/efectos adversos , Intervención Coronaria Percutánea/métodos , Inhibidores de Agregación Plaquetaria/efectos adversos , Puntaje de Propensión , Trombosis/etiología , Ticagrelor/efectos adversos , Resultado del Tratamiento , Ultrasonografía Intervencional/efectos adversos
2.
Biochem Cell Biol ; 99(5): 655-665, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-33939927

RESUMEN

Increasing evidence has shown that the NOD-like receptor protein 3 (NLRP3) inflammasome and pyroptotic cell death play vital roles in the pathophysiology of myocardial infarction (MI), a common cardiovascular disease characterized by cardiac dysfunction. C-type lectin member 5A (CLEC5A) has been reported to be strongly associated with activation of the NLRP3 inflammasome and pyroptosis. In this study, an in vivo MI model was established by ligation of the left anterior descending coronary artery in male C57BL/6 mice, and CLEC5A knockdown was further achieved by intra-myocardial injection of adenovirus delivering shRNA-CLEC5A. CLEC5A was found to be highly expressed in the left ventricle of MI mice, while CLEC5A knockdown alleviated cardiac dysfunction in MI mice. In addition, MI-induced classical activation of macrophages was significantly inhibited after CLEC5A silencing. Additionally, CLEC5A knockdown dramatically inhibited MI-triggered activation of NLRP3 inflammasome, pyroptosis, and NF-κB signaling in the left ventricle of mice. In vitro experiments further validated that CLEC5A knockdown suppressed M1 polarization in LPS/IFNγ-stimulated RAW264.7 cells and inhibited the polarized RAW264.7-induced activation of NLRP3 inflammasome/pyroptosis signaling in co-cultured cardiomyocytes. In conclusion, CLEC5A knockdown protects against MI-induced cardiac dysfunction by regulating macrophage polarization, NLRP3 inflammasome, and cell pyroptosis.


Asunto(s)
Cardiomiopatías/metabolismo , Inflamasomas/metabolismo , Lectinas Tipo C/metabolismo , Macrófagos/metabolismo , Infarto del Miocardio/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Receptores de Superficie Celular/metabolismo , Animales , Cardiomiopatías/patología , Células Cultivadas , Lectinas Tipo C/deficiencia , Macrófagos/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Infarto del Miocardio/patología , Piroptosis , Células RAW 264.7 , Receptores de Superficie Celular/deficiencia
3.
Zhongguo Shi Yan Xue Ye Xue Za Zhi ; 31(4): 1026-1031, 2023 Aug.
Artículo en Zh | MEDLINE | ID: mdl-37551472

RESUMEN

OBJECTIVE: To explore and summarize the clinical characteristics and treatment of aggressive NK-cell leukemia (ANKL), and provide new insights for clinical diagnosis and treatment of this disease. METHODS: The clinical data of 7 patients with ANKL admitted to the First Affiliated Hospital of Wannan Medical College from March 2014 to July 2021 were retrospectively analyzed, and their clinical characteristics, laboratory and imaging results, treatment and outcomes were analyzed. RESULTS: Among the 7 patients, 5 were males and 2 were females, with a median age of 47 (33-69) years old. The morphology of bone marrow cells in 7 patients showed similar large granular lymphocytes. Immunophenotyping revealed abnormal NK cells in 5 cases. By the end of follow-up, 6 cases died and 1 case survived, with a median survival time of 76.9 (4-347) days. CONCLUSION: ANKL is a rare disease with short course and poor prognosis. If combined with hemophagocytic syndrome (HPS), the prognosis is even worse. There is no unified treatment method at present, and the use of PD-1 inhibitors may prolong the survival in some patients.


Asunto(s)
Leucemia Linfocítica Granular Grande , Leucemia Prolinfocítica de Células T , Linfohistiocitosis Hemofagocítica , Masculino , Femenino , Humanos , Persona de Mediana Edad , Anciano , Estudios Retrospectivos , Pronóstico
4.
Chin Med J (Engl) ; 128(8): 1026-31, 2015 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-25881594

RESUMEN

BACKGROUND: In cardiology, it is controversial whether different therapy strategies influence prognosis after acute coronary syndrome. We examined and compared the long-term outcomes of invasive and conservative strategies in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and characterized the patients selected for an invasive approach. METHODS: A total of 976 patients with acute NSTEMI were collected from December 2006 to October 2012 in the First Affiliated Hospital of Dalian Medical University Hospital. They are divided into conservative strategy (586 patients) and invasive strategy (390 patients) group. Unified follow-up questionnaire was performed by telephone contact (cut-off date was November, 2013). The long-term clinical events were analyzed and related to the different treatment strategies. RESULTS: The median follow-up time was 29 months. Mortality was 28.7% (n = 168) in the conservative group and 2.1% (n = 8) in the invasive management at long-term clinical follow-up. The secondary endpoint (the composite endpoint) was 59.0% (n = 346) in the conservative group and 30.3% (n = 118) in the invasive management. Multivariate analysis showed that patients in the conservative group had higher all-cause mortality rates than those who had the invasive management (adjusted risk ratio [RR] = 7.795; 95% confidence interval [CI]: 3.796-16.006, P < 0.001), and the similar result was also seen in the secondary endpoint (adjusted RR = 2.102; 95% CI: 1.694-2.610, P < 0.001). In the subgroup analysis according to each Thrombolysis in Myocardial Infarction risk score (TRS), log-rank analysis showed lower mortality and secondary endpoint rates in the invasive group with the intermediate and high-risk patients (TRS 3-7). CONCLUSIONS: An invasive strategy could improve long-term outcomes for NSTEMI patients, especially for intermediate and high-risk ones (TRS 3-7).


Asunto(s)
Infarto del Miocardio/patología , Síndrome Coronario Agudo/mortalidad , Síndrome Coronario Agudo/patología , Síndrome Coronario Agudo/terapia , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Infarto del Miocardio/mortalidad , Infarto del Miocardio/terapia , Pronóstico , Estudios Retrospectivos
5.
Mol Divers ; 11(2): 73-80, 2007 May.
Artículo en Inglés | MEDLINE | ID: mdl-17566867

RESUMEN

A simple and effective method for the synthesis of bioactive imidazo[1,2,4]triazole analogues has been developed utilizing the MCR technique, which involved the reaction of aminotriazoles, isocyanides and aldehydes. The products were characterized by (1)H, (13)C NMR spectroscopy, MS and elemental analysis. Interestingly, compounds 19d, 21a, 21b and 21h displayed good cytotoxic activities at 10(-4) M concentration in the inhibition of tumor cell growth as evaluated by the MTT method.


Asunto(s)
Imidazoles/síntesis química , Triazoles/síntesis química , Animales , Antibacterianos/síntesis química , Antibacterianos/farmacología , Catálisis , Células Cultivadas , Evaluación Preclínica de Medicamentos , Humanos , Imidazoles/farmacología , Ratones , Modelos Biológicos , Staphylococcus aureus/efectos de los fármacos , Relación Estructura-Actividad , Triazoles/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA